ES2149761T3 - Derivado de piridazinona. - Google Patents

Derivado de piridazinona.

Info

Publication number
ES2149761T3
ES2149761T3 ES91907712T ES91907712T ES2149761T3 ES 2149761 T3 ES2149761 T3 ES 2149761T3 ES 91907712 T ES91907712 T ES 91907712T ES 91907712 T ES91907712 T ES 91907712T ES 2149761 T3 ES2149761 T3 ES 2149761T3
Authority
ES
Spain
Prior art keywords
piridazinone
derived
salt
vasodilatory
cardiotonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907712T
Other languages
English (en)
Spanish (es)
Inventor
Keizo Tanikawa
Akira Saito
Takashi Matsumoto
Ryozo Sakoda
Nobutomo Tsuruzoe
Ken Shikada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Application granted granted Critical
Publication of ES2149761T3 publication Critical patent/ES2149761T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES91907712T 1990-04-25 1991-04-19 Derivado de piridazinona. Expired - Lifetime ES2149761T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10991490 1990-04-25

Publications (1)

Publication Number Publication Date
ES2149761T3 true ES2149761T3 (es) 2000-11-16

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907712T Expired - Lifetime ES2149761T3 (es) 1990-04-25 1991-04-19 Derivado de piridazinona.

Country Status (17)

Country Link
US (3) US5202323A (enExample)
EP (1) EP0482208B1 (enExample)
JP (1) JPH07107055B2 (enExample)
KR (1) KR970002876B1 (enExample)
AT (1) ATE194835T1 (enExample)
AU (1) AU634655B2 (enExample)
CA (1) CA2053863C (enExample)
DE (1) DE69132329T2 (enExample)
DK (1) DK0482208T3 (enExample)
ES (1) ES2149761T3 (enExample)
GR (1) GR3034331T3 (enExample)
HU (1) HU208124B (enExample)
RU (1) RU2054004C1 (enExample)
TW (1) TW204348B (enExample)
UA (1) UA27031A1 (enExample)
WO (1) WO1991016314A1 (enExample)
ZA (1) ZA913134B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
EP0717734B1 (en) * 1993-09-06 1998-11-18 Ishihara Sangyo Kaisha, Ltd. Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
TW326041B (en) * 1993-12-16 1998-02-01 Nippon Nouyaku Kk Pyridazinone derivatives, their production process and their use for inhibition of platelet aggregation
US5750523A (en) * 1994-01-25 1998-05-12 Nissan Chemical Industries, Ltd. Pyridazinone derivatives
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
CZ297769B6 (cs) 1996-06-27 2007-03-28 Janssen Pharmaceutica N. V. N-[4-(heteroarylmetyl)fenyl]-heteroarylaminy, zpusob jejich prípravy a jejich pouzití jako léciva
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
EP1025847B1 (en) 1997-08-28 2005-10-26 Nissan Chemical Industries, Ltd. Neovascularization promoters and neovascularization potentiators
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
ATE272401T1 (de) * 1998-09-01 2004-08-15 Nissan Chemical Ind Ltd Heilmittel für die stenose des rückenmarkkanals
UA73104C2 (en) * 1998-12-07 2005-06-15 Nissan Chemical Ind Ltd Erectile dysfunction remedy comprising 3(2h)-pyridazinone derivative
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
CA2439593C (en) * 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
CA2447618A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1913942B1 (en) * 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
KR20060125816A (ko) * 2003-12-26 2006-12-06 닛산 가가쿠 고교 가부시키 가이샤 호중구증다 억제제
RU2339381C2 (ru) * 2004-02-09 2008-11-27 Ниссан Кемикал Индастриз, Лтд. Ингибитор гиперплазии интимы сосудов
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2374805A4 (en) * 2008-12-25 2012-06-27 Nissan Chemical Ind Ltd PYRIDAZINE-3 (2H) -ONE HYDROCHLORIDE COMPOUND CRYSTALS AND METHOD FOR THE PRODUCTION THEREOF
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2535048A4 (en) 2010-02-12 2013-08-14 Taisho Pharmaceutical Co Ltd PREPARATION WITH DELAYED RELEASE
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CA2922943A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
BR112020024427A2 (pt) 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
CA1265798A (en) * 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
ZW20586A1 (en) * 1985-10-17 1988-05-25 Smith Kline French Lab Chemical compounds
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat

Also Published As

Publication number Publication date
UA27031A1 (uk) 2000-02-28
US5202323A (en) 1993-04-13
CA2053863A1 (en) 1991-10-26
RU2054004C1 (ru) 1996-02-10
TW204348B (enExample) 1993-04-21
US5318968A (en) 1994-06-07
AU634655B2 (en) 1993-02-25
KR920701169A (ko) 1992-08-11
HU913497D0 (en) 1992-01-28
EP0482208A1 (en) 1992-04-29
JPH07107055B2 (ja) 1995-11-15
HUT60253A (en) 1992-08-28
DE69132329T2 (de) 2000-11-30
ZA913134B (en) 1992-04-29
DK0482208T3 (da) 2000-09-18
WO1991016314A1 (en) 1991-10-31
US5314883A (en) 1994-05-24
CA2053863C (en) 1996-10-29
DE69132329D1 (de) 2000-08-24
HU208124B (en) 1993-08-30
EP0482208A4 (en) 1992-10-07
JPH07107055B1 (enExample) 1995-11-15
ATE194835T1 (de) 2000-08-15
EP0482208B1 (en) 2000-07-19
KR970002876B1 (ko) 1997-03-12
AU7651191A (en) 1991-11-11
GR3034331T3 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
ES2149761T3 (es) Derivado de piridazinona.
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
AU7815791A (en) Heterocyclene derivatives
DK0807633T3 (da) Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
FI905280A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivista bentsopyridopiperidiini-, piperidylideeni- ja -piperatsiiniyhdistettä
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
AP9701041A0 (en) Pyridylpyrrole compounds.
HUT62893A (en) Process for producing substituted pyrimidine derivatives and pharmaceutical compositions comprising such compounds as active ingredient
AU7436691A (en) Novel 2,9-disubstituted-4H-pyrido(1,2-a)pyrimidin-4-ones
GB9502644D0 (en) Heterocyclic derivatives
NO173444C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 4-(4'- fluorfenyl-)-tienopyridin-derivater
ZA979647B (en) Heterocyclic compounds, compositions and uses.
NO910904D0 (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
ZA979650B (en) Heterocyclic compounds, compositions and uses.
ZA979645B (en) Heterocyclic compounds, compositions and uses.
NO164474C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heksahydropyrrolo(2,1-a)isokinolin-derivater.
DE3372772D1 (en) Quinazolinone derivatives, process for their preparation and their use in medicaments
ATE10934T1 (de) Peptid, verfahren zu dessen herstellung und dessen verwendung.
SE9304065D0 (sv) New compound

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 482208

Country of ref document: ES